Primary neoplastic conditions of the anal canal are uncommon. Although their diagnosis and follow-up are traditionally based on clinical assessment, imaging, particularly MRI, plays an important role in staging and follow-up after treatment. In this article, we discuss and illustrate the current role of MRI in the pre and post-therapeutic management of these patients.

Although a rare disease, anal cancer is increasingly being diagnosed in patients with risk factors, mainly anal infection with the human papilloma virus. Magnetic resonance imaging (MRI) with external phased-array coils is recommended as the imaging modality of choice to grade anal cancers and to evaluate the response assessment after chemoradiotherapy, with a high contrast and good anatomic resolution of the anal canal. MRI provides a performant evaluation of size, extent and signal characteristics of the anal tumor before and after treatment, as well as lymph node involvement and extension to the adjacent organs. MRI is also particularly helpful in the assessment of complications after treatment, and in the diagnosis for relapse of the diseases.

Keywords: Anus; Anal cancer; Diagnosis; Staging; Magnetic resonance imaging

INTRODUCTION

Primary neoplastic conditions of the anal canal are uncommon. Although their diagnosis and follow-up are traditionally based on clinical assessment, imaging, particularly MRI, plays an important role in staging and follow-up after treatment. In this article, we discuss and illustrate the current role of MRI in the pre and post-therapeutic management of these patients.

Anatomical and Histological Relevant Notions

The anal canal extends from the anorectal junction to the anal margin, and is usually 3–6 cm in length. The anal margin is the circular rim of pigmented skin with folds surrounding the anus. The anal canal is composed of an internal sphincter and an external sphincter complex. The internal sphincter is the distal continuation of the inner circular rectal muscular layer, while the external sphincter complex includes the inferior confluence of the levator ani muscle, the puborectalis sling, and the deep, subcutaneous, superficial external sphincter muscles. Both sphincters are separated by the fatty intersphincteric space (Figs. 1, 2).

A significant marker of the anal canal is the dentate line, separating the upper part lined with transitional zone or rectal glandular mucosa, and the lower part (distal third) lined by nonkeratinizing squamous epithelium. Tumors located above the dentate line drain into the perirectal and internal iliac nodes, whereas tumors below the dentate line drain into the inguinal and femoral lymph nodes. The dentate line cannot be seen on MRI, but its position can...
be estimated by dividing the anal canal into thirds, so that
the dentate line lies at the junction of the upper one-third
and lower two-thirds. The current World Health Organization
distinguishes invasive tumors as epithelial tumors (squamous
cell carcinoma, adenocarcinoma, mucinous adenocarcinoma,
small cell carcinoma, undifferentiated carcinoma),
nonepithelial tumors (leiomyoma, gastrointestinal tumor,
myofibroma), carcinoid tumors and melanomas. Virtually all
anal canal cancers (AC) are squamous, either keratinizing
or non-keratinizing, according to their origin below or
above the dentate line, although with similar biological
behaviour. As far as tumors near the anorectal junction are
concerned, the American Joint Committee on Cancer (AJCC)
recommends that tumors with an epicenter more than 2 cm
superior to the dentate line should be staged as low rectal
carcinomas, whereas the others tumors should be staged as
AC (1). In practice, however, the precise point of origin is
often uncertain at diagnosis.

**Epidemiology of Anal Cancer**

Anal canal cancers are uncommon, with an incidence
of 1.5:100000 persons per year (2). Their rate has been
steadily increasing, due to the rising prevalence of the
strongest risk factors, the human immunodeficiency virus
(HIV), and human papilloma virus (HPV), mainly HPV-16
subtype (3-5). Although the overall incidence of AC remains
higher among women, it is much higher in men who practice
anoreceptive intercourse (4). AC is also strongly associated
with immune suppression in transplant recipients (3). Other
risk factors include cervical dysplasia, autoimmune disorders
and cigarette smoking (4). Some reports have also shown
an increased risk of anal cancer with long-standing, severe
perianal fistulizing Crohn’s disease (5-7). In these cases, AC
occurs at a younger age. Diagnosis is often delayed, and at
an advanced stage the prognosis is grave.

**Clinical Diagnosis and Treatment of Anal Cancer**

Diagnosis of these tumors is often delayed as they
commonly present with bleeding that is generally attributed
to hemorrhoids. They may also manifest as any combination
of a mass, non-healing ulcer, pain, itching, discharge,
fecal incontinence and fistula. The diagnosis of anal
cancer is made on biopsy-proven histology. More advanced
lesions in the distal anal canal may extend to the skin at
the anal margin. Rarely, patients present with inguinal
lymphadenopathy.

Anal margin tumors can be treated by surgical
excision alone, as opposed to anal canal tumors, which
have a worse prognosis and are treated with definitive
chemoradiotherapy.
A multidisciplinary approach is mandatory. Large prospective validated randomized controlled trials (8-12) support the use of radiotherapy with a dose ranging between 45 and 50 Gy, combined with mitomycin-C and infusional 5-FU chemotherapy as the standard of care for all AC. This leads to complete tumor regression in 80–90% of patients, with locoregional failures of up to 15% (13). Standard radiation fields include the pelvis, anus, perineum, and inguinal nodes. Inguinal nodes receive a booster dose if there is evidence of gross nodal disease (14). The incidence of nodal involvement increases with increasing primary tumor size, and is at least 20% in patients with T3 disease (15). In case of surgical treatment, abdomino-perineal resection is performed for salvage in patients with locally recurrent disease, or for non-responsive patients with persistent tumors (13). Local excision may be performed.

**Fig. 3.** MR signal of anal canal squamous cell carcinomas.  
A, B. Axial (A) and coronal (B) T2-weighted MR images show high signal intensity tumor (arrow) relative to muscles, and of low signal intensity relative to normal ischioanal fat. Lesion is staged T2. C. On low b value of axial diffusion-weighted MR images, lesion shows hyperintensity (arrow). D. Lesion (arrow) is markedly enhanced on fat-suppressed contrast-enhanced T1-weighted axial MR image.
in case of smaller lesions (< 2 cm in diameter), those involving the anal margin, and well differentiated lesions (13). In these cases, it is important to adequately stage the lesion in order to rule out the presence of positive nodes. Lastly, metastatic disease is considered incurable.

**MRI Protocol**

Most studies dealing with MRI of AC have been performed at 1.5T (14-16). No specific patient preparation is required. Although some teams use antispasmodolytic agents to obtain good quality MR images (16-19), we did not find this a necessity. As for rectal cancer (20), insertion of a probe in the anal canal does not seem to be necessary either. Adequate coverage of the anal margin, inguinal areas and higher nodal stations, i.e., at least the sacral promontory and the area below the aortic bifurcation, should be obtained. Some authors also add T1-weighted MR sequences up to the renal hilum (21). MR protocols include high-resolution T2-weighted sequences along the three planes, with coronal and axial scans planned parallel and perpendicular to the long axis of the anal canal. Slice thickness for imaging the tumor is generally kept under 4 mm (16-19, 22, 23), with a small field of view.

Most authors (16-20) use additional short-tau inversion recovery sequences. Despite their limited spatial detail, these sequences are helpful for identifying fistula tracts present at the initial staging, or those developing during the treatment. We also use gadolinium-enhanced fat-suppressed T1-weighted sequences in at least one plane, in order to enhance delineation of the relationships of the tumor to the sphincters, and detect lesion enhancement, as has been previously reported (19, 14).

Diffusion-weighted imaging appears to have an emerging role (23), especially for differentiating suspected small residual/recurrent tumors from treatment-related changes; however, no dedicated studies on the potential added value of these MRI sequences have been published so far.

**Radiologic Staging of Anal Cancer**

**Role of Imaging Modalities**

On diagnosis of primary anal cancer, the specific standard workup includes a digital rectal examination and anoscopy, inguinal lymph node assessment with biopsy of the nodes if indicated, and systemic radiologic evaluation. The latest European Society for Medical Oncology (ESMO) recommendations published in 2014 (13) advocates the use of phased-array MRI of the pelvis, or if not available, endo-anal ultrasound (EUS). EUS has a limited scope compared with MRI, since it does not provide data on many of the regional nodal stations for anal cancer, and is operator dependent and unable to assess stenotic tumors. Owing to its small field of view, it is best reserved for small T1 lesions.

Computed tomography (CT) of the thorax and abdomen is used to assess distant extent of spread, mainly metastasis in liver and lungs, which is present in less than 10% of cases. 18-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT has an increasing role in staging and treatment planning of anal carcinoma. Up to 98% of anal tumors are FDG-avid. At diagnosis, FDG PET/CT is used to evaluate primary tumor size, lymph node status, and the presence of distant metastases. Several studies (24-26) report the increased sensitivity of FDG PET/CT compared with contrast-enhanced CT for detection of abnormal lymph nodes, especially for advanced T2 tumors, with a change in staging of the anal carcinoma in about 20% of the cases (27). However, these studies remain limited, because...
Histological confirmation of FDG-avid nodes is lacking.

**MRI Features of Anal Malignancies**

Sensitivity of MRI for the identification of AC has been reported to approach 90–100%, with high concordance regarding tumor size, compared to transanal endoscopic ultrasound (28). Position (anal canal, anal margin), circumferential tumor extent (position on clock), and subjective T2-weighted signal intensity (high-similar to fluid; low- similar to muscle and intermediate) need to be noted. Infiltration of adjacent organs (vagina, prostate), transspincteric extension into the ischioanal/ischiorectal fossa, and the presence of perianal fistulas or abscesses are also recorded.

Anal cancers display high signal intensity relative to skeletal muscles on T2-weighted images, but lower than normal ischioanal fat, and low to intermediate signal intensity on T1-weighted images. They are markedly enhanced after intravenous gadolinium contrast injection (Fig. 3) (17-19, 29). Anal cancers can extend to the rectum with skip lesions seen at a distance from the primary site, involving low or even middle rectum. They may develop on condylomas, particularly in HIV and HPV positive patients (Figs. 4, 5).

Radiologists should be aware of the possibility of neoplastic changes in long-standing anorectal fistulas, and should be alerted by the presence of soft tissue within the fistula (30). In such cases, AC will generally display T2
Table 1. TNM Classification, 8th Edition (27)

| T0  | No evidence of primary tumor | Nx  | No regional lymph node metastasis | M0  | No distant metastasis |
|-----|----------------------------|-----|----------------------------------|-----|-----------------------|
| Tis | Carcinoma in situ           | N1  | Metastasis in regional lymph node(s) | M1  | Distant metastasis    |
| T1  | Tumor 2 cm or lesser in greatest dimension | N1a | Metastasis in inguinal, mesorectal and/or internal iliac nodes | T2  | No more than 2 cm but no more than 5 cm in greatest dimension | N1b | Metastasis in external iliac nodes |
| T3  | Tumor more than 5 cm in greatest dimension | N1c | Metastases in external iliac and in inguinal, mesorectal and/or internal iliac nodes |
| T4  | Tumor of any size invades adjacent organs (e.g., vagina, urethra, bladder); direct invasion of rectal wall, perirectal skin, subcutaneous tissues or sphincter muscle(s) is not classified as T4 |

Fig. 7. Squamous cell carcinoma of anal canal in 62-year-old man, T2N0M0. Twenty-two mm lesion is seen invading internal and external sphincter, without extension to adjacent organs, on axial (arrow, A), T2-weighted, high b value (b 1000) (arrow, B), and fat-suppressed gadolinium-enhanced T1-weighted (arrow, C) MR images.

Fig. 8. Squamous cell carcinoma of anal canal, T4N1aM0, in 73-year-old woman. Lesion has cranio-caudal extension of 85 mm, invading middle rectum, vagina and uterine cervix. Axial T2 (A), sagittal T2 (B), and axial fat-suppressed contrast-enhanced T1-weighted MR image (C) show extension of lesion to vagina (white arrows, A, B), skip lesion to mid rectum (black arrow, B) and extension to uterine cervix (white arrow, C).
-weighted high signal intensity, due to colloid content and mesh like internal enhancement (Fig. 6).

Anal melanoma is rare, accounting for only 2% of all melanomas (31), and is generally homogeneous. Primary anal lymphomas are also very rare, and appear as a mass with focal and/or circumferential thickening of the anal canal, potentially extending into the rectum, mildly enhancing after contrast medium injection, and typically without luminal obstruction (32).

Staging of Anal Tumors

T stage corresponds to the size of the primary tumor (Table 1), assessed by measuring the tumor in its longest diameter on T2-weighted MR images (Figs. 7-9) (27), but does not take into account the extension to the sphincters. As far as stage T4 is concerned, the ESMO defined that the invasion of the following organs for anal canal carcinoma does not affect T4 staging: external and/or internal sphincter muscles, rectal wall, puborectalis muscle, levator ani muscle and vestibule for tumors originating from the anal margin. For anal margin carcinoma, a T4 lesion is defined by invasion of deeper structures such as the skeletal muscle or cartilage. Unlike N staging for rectal cancer, the location of nodal stations involved determines the N stage for anal cancer (15).

Proximal lymphatic drainage is to perirectal nodes along the inferior mesenteric artery. Infra-dentate and perianal skin tumors drain to the inguinal, femoral and external iliac nodes. Immediately above the dentate line, drainage is to internal pudendal nodes, and to the internal iliac system. All lymph nodes behind the external iliac vessels are considered to belong to the obturator fossa, and are thus a part of the internal iliac group. Nodes along the external iliac vessels are considered as distant spread. Criteria for diagnosis of lymph node metastasis are not validated, but enlargement (largest short- axis diameter > 1 cm for mesorectal nodes, and > 1.5 cm for other nodes), heterogeneity or necrosis, irregular contours and strong enhancement are considered to suggest involvement (Fig. 10) (21, 29).

Role of Imaging for Tumor Response Assessment and Detection of Recurrence

Fifty per cent of recurrences occurring within the first 2 years post treatment are located around the primary site of disease, or as pelvic/inguinal lymph nodes (22). ESMO recommends clinical evaluation for complete response at 8 weeks post chemoradiotherapy (CRT), with a 3-to 6-monthly follow up thereafter for a 2-year period, stating that “MRI can capture and document response, but no individual MRI
Fig. 11. Ano-vaginal fistula in 63-year-old woman, 6 months after chemoradiation therapy for T3N1cM0 squamous cell carcinoma of anal canal.
Axial T2 (A), and fat-suppressed contrast-enhanced T1-weighted MR (B) images display large fistula from treated anterior part of anal canal into vagina (arrows).

Fig. 12. 63-year-old woman with squamous cell carcinoma of anal canal, T2N1aM0.
Twenty-five-mm lesion of anal canal shows high signal intensity on T2-weighted image (arrow, A), with strong enhancement on contrast-enhanced T1-weighted (arrow, B). MRI control after CRT shows lesion with peripheral enhancement on contrast-enhanced T1-weighted image (arrow, C), corresponding to radionecrosis.
feature appears predictive of eventual outcome” (15). The use of imaging in patients following CRT is still debatable, and there is scarce data in the literature on assessment of tumor response using imaging modalities.

Other international recommendations do not endorse a role of MRI in post CRT surveillance (33, 34). However, these recommendations are based on series of very small sample size (17, 18, 29); in current practice, MRI often serves as the follow-up imaging modality (16, 17, 35). Although consensus criteria for response have not been described so far, reduction in tumor size, as well as in T2-weighted signal intensity of the treated tumor or associated lymphadenopathy, is indicative of response. The optimal timing for therapy assessment has so far not been defined, but size involution seems to be most evident at 6 months post treatment, and complete response has been reported to occur at around 26 weeks (18). Clinicians generally ask for the MRI to be performed 8 weeks after CRT completion, in accordance with what is established for rectal cancers. This time point is likely to be too early, as not all tumors will have achieved complete response, and also since inflammation is superimposed on the treated cancer.

A retrospective study by Kochhar et al. (16), comprising of 74 patients with non-metastatic anal squamous cell carcinoma with a demonstrable anal lesion on baseline staging treated with CRT undergoing 3 and 6 months MRI follow-up, has recently shown that tumor regression grade (TRG) 1/2 scores at 3 and 6 months had a 100% negative predictive value, and that TRG 4/5 scores at 6 months had a 100% positive predictive value. However, no imaging characteristic or TRG score independently prognosticated for late relapse or 3-year disease free survival (16). Reduction in size was seen at 3 (mean 28.79%) and 6 months (mean 81.39%), and reduction in signal intensity was recorded in 69% and 84% of patients at 3 and 6 months, respectively. Nodal disease was downstaged in 33/36 patients, with N0 status in 32 of these patients. The benefit of FDG-PET/CT studies seems to be detection of residual sub-clinical pelvic or extra-pelvic/para-aortic node involvement, rather than assessment of tumor response (13).

**Complications Post-CRT**

Radiation proctitis as well as fistula (Fig. 11) and abscesses may complicate radiotherapy. Radionecrosis is an uncommon event occurring in up to 10% of patients undergoing radiotherapy for anal cancer (36). It causes clinical (pain, anal stenosis, mucositis and diarrhea) and diagnostic problems. MRI finding of a hypointense area on T1/T2-weighted MR images with only a peripheral enhancement rim, is suggestive of this diagnosis (Fig. 12).

**MRI of Recurrent Tumors**

Recurrent disease is defined as initial complete response to therapy, with subsequent positive biopsies, more than six months after completion of treatment. Patients with recurrent disease may benefit from surgical salvage (13), and MRI is the best post-operative imaging modality. Similar to rectal cancers (37), T2-weighted-hypointense signal at the site of the primary tumor after CRT, is a morphological sign consistent with response, as it represents fibrosis. However, MRI is unable to reliably exclude residual neoplastic foci within the fibrosis. Recently, Kochhar et al. (16) have described a novel ‘tram track’ sign on post-CRT scans, defined as parallel linear low signal at the inner and outer margin of the internal sphincter at the site of the original tumor. This sign had a negative predictive value for early local relapse of 83% at 6 months, and was present in more than half the patients (16). CT scan of thorax and abdomen (or PET/CT) is advised to rule out distant metastases. Tumors that are likely to relapse include tumors larger than 4 cm, with nodal involvement, and basaloid subtypes (23).

**CONCLUSION**

Having a high contrast and good anatomic resolution of the anal canal, magnetic resonance imaging is the imaging modality of choice to stage anal cancers, to evaluate response assessment after CRT, and to detect complications.

**REFERENCES**

1. American Joint Committee on Cancer. AJCC cancer staging manual, 7th ed. New York: Springer, 2010:103-106
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
3. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004;101:281-288
4. Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist 2007;12:524-534
5. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal
Cancer of the Anal Canal: Diagnosis, Staging and Follow-Up with MRI

6. Barral M, Dohan A, Allez M, Boudiaf M, Camus M, Laurent V, et al. Gastrointestinal cancers in inflammatory bowel disease: an update with emphasis on imaging findings. *Crit Rev Oncol Hematol* 2016;97:30-46

7. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. *Lancet* 1996;348:1049-1054

8. Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. *J Clin Oncol* 2012;30:1941-1948

9. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA* 2008;299:1914-1921

10. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. *J Clin Oncol* 1996;14:2527-2539

11. Bartelink H, Roelofs F, Eschwege F, Rougié P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol* 1997;15:2040-2049

12. Sjödahl RI, Myrelid P, Söderholm JD. Anal and rectal cancer in Crohn’s disease. *Color Dis* 2003;5:490-495

13. Glyne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014;25 Suppl 3:iili10-20

14. Matalon SA, Mamou HJ, Fuchs CS, Doyle LA, Tirumani SH, Ramaiya NH, et al. Anorectal cancer: critical anatomic and staging distinctions that affect use of radiation therapy. *Radiographics* 2015;35:2090-2107

15. Jones M, Hruby G, Stanwell P, Gallagher S, Wong K, Arm J, et al. Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. *BMC Cancer* 2015;15:281

16. Kochhar R, Renehan AG, Mullan D, Chakrabarty B, Saunders MP, Carrington BM. The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer. *Eur Radiol* 2017;27:607-617

17. Goh V, Gollub FK, Liaw J, Wellsted D, Przybytniak I, Padhani AR, et al. Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? *Int J Radiat Oncol Biol Phys* 2010;78:715-721
34. Steele SR, Varma MG, Melton GB, Ross HM, Rafferty JF, Buie WD; Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for anal squamous neoplasms. Dis Colon Rectum 2012;55:735-749

35. Renehan AG, O’Dwyer ST. Management of local disease relapse. Colorectal Dis 2011;13 Suppl 1:44-52

36. Borzomati D, Valeri S, Ripetti V, Vincenzi B, Rabitti C, Persichetti P, et al. Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication? Hepatogastroenterology 2005;52:780-784

37. Hoeffel C, Mulé S, Laurent V, Pierredon-Foulogne MA, Soyer P. Current imaging of rectal cancer. Clin Res Hepatol Gastroenterol 2015;39:168-173